Compare Aegon Ltd. (AEG) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aegon Ltd. vs AstraZeneca plc — how do they compare? Aegon Ltd. trades at $9.42 (market cap $14.01B), while AstraZeneca plc trades at $158.63 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 17.7× Aegon Ltd.'s market cap, and Aegon Ltd. pays the higher dividend (4.94%). Which is the better fit depends on your goals.
| AEG | AZN | |
|---|---|---|
Market Cap | $14.01B | $248.14B |
Sector | Financials | Health |
52-Week High | $9.53 | $209.48 |
52-Week Low | $6.79 | $147.06 |
Enterprise Value | $15.16B | $275.41B |
Dividend Yield | 4.94% | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AEG trades at $9.41, down 0.48% with a bullish technical signal from moving averages. The company shows improving fundamentals with revenue growth from $19.5B in 2024 to $26.9B in 2025 and net income increasing to $977M. Recent strategic moves include relocating to Delaware and simplifying governance while maintaining a dividend payout. Analyst consensus is mixed with 28% buy ratings but 50% hold recommendations.
AEG presents a turnaround story with improving profitability and strategic refocusing on US markets. Key opportunities include continued earnings growth and potential buybacks, while risks involve execution of the US transition and maintaining momentum amid volatile cash flow patterns. The stock offers value with a P/E of 13.5 and P/S of 0.57.
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
